Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 40, Issue 3, Pages 212-225Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2019.01.004
Keywords
-
Categories
Funding
- Natural Sciences and Engineering Research Council of Canada
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
- Pfizer/ASPIRE Cardiovascular Research Awards
Ask authors/readers for more resources
Interest in lipoprotein (a) [Lp(a)] has exploded over the past decade with the emergence of genetic and epidemiological studies pinpointing elevated levels of this unique lipoprotein as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). This review summarizes the most recent discoveries regarding therapeutic approaches to lower Lp(a) and presents these findings in the context of an emerging, although far from complete, understanding of the biosynthesis and catabolism of Lp(a). Application of Lp(a)-specific lowering agents to outcome trials will be the key to opening this new frontier in the battle against CVD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available